Linavonkibart is a monoclonal antibody commercialized by Scholar Rock Holding, with a leading Phase I program in Ovarian Cancer;Uterine Cancer. According to Globaldata, it is involved in 1 clinical trial, which is ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of Linavonkibart’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Linavonkibart is expected to reach an annual total of $139 mn by 2038 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Linavonkibart Overview
Linavonkibart (SRK-181) is under development for the treatment of solid tumors including but not limited to bladder cancer, myelofibrosis, head and neck squamous cell carcinoma (HNSCC), urothelial cancer, non-small cell lung cancer, melanoma, clear cell renal cell carcinoma (ccRCC), myelofibrosis , breast cancer and ovarian cancer, oropharyngeal cancer, nasopharyngeal cancer, liver cancer, uterine cancer, prostate cancer and colorectal cancer. It acts by targeting transforming growth factor beta 1 (TGFB1). The drug candidate is developed using the supracellular activation technology platform.
Scholar Rock Holding Overview
Scholar Rock Holding (Scholar Rock) is a late-stage biopharmaceutical company that discovers, develops and delivers innovative medicines for the treatment of serious diseases. The company’s pipeline products include apitegromab, a human monoclonal antibody that inhibits myostatin activation that targets spinal muscular atrophy; SRK-439, an investigational myostatin inhibitor that treats cardiometabolic disorders; SRK-181, an inhibitor of the activation of latent transforming growth factor beta for cancers treatment; and potent and selective inhibitors of the activation of TGFß for the treatment of fibrotic diseases. The company has collaborated with Gilead Sciences Inc to discover and develop specific inhibitors. Scholar Rock is headquartered in Cambridge, Massachusetts, the US.
The operating loss of the company was US$171.3 million in FY2023, compared to an operating loss of US$134.4 million in FY2022. The net loss of the company was US$165.8 million in FY2023, compared to a net loss of US$134.5 million in FY2022.
For a complete picture of Linavonkibart’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.